Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 57Melanoma 54Neoplasm Metastasis 49Lung Neoplasms 49Breast Neoplasms 41Neoplasms 36Colorectal Neoplasms 35Head and Neck Neoplasms 25Endometrial Neoplasms 25Carcinoma, Renal Cell 24Uterine Cervical Neoplasms 21Stomach Neoplasms 21Ovarian Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 16Recurrence 15Carcinoma, Hepatocellular 14Pancreatic Neoplasms 13Sarcoma 12Carcinoma, Squamous Cell 12Glioblastoma 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Prostatic Neoplasms 10Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

selinexor 2Ifosfamide 2Doxorubicin 2pembrolizumab 1pazopanib 1metarrestin 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Proton Therapy 1Nivolumab 1Mesna 1Liquid Biopsy 1Injections 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neurofibrosarcoma × pembrolizumab × Clear all
NCT05732831 2026-04-21

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics, Inc.

Phase 1/2 Recruiting
225 enrolled
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡